Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
30 June 2019 |
Main ID: |
EUCTR2012-002699-14-GB |
Date of registration:
|
03/07/2012 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Trial of inhaled mannitol in children with cystic fibrosis
|
Scientific title:
|
A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years - DPM-CF-204 mannitol in CF aged 6-17 years |
Date of first enrolment:
|
28/01/2013 |
Target sample size:
|
160 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002699-14 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: yes Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Belgium
|
Canada
|
France
|
Italy
|
Netherlands
|
United Kingdom
| |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
N/A |
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
N/A |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Personally provide, or have a legal guardian provide written informed consent to participate in the trial, according to local regulations; 2. rhDNase and maintenance antibiotic use is allowed but treatment must have been established at least 3months prior to screening. The subject must remain on rhDNase and / or maintenance antibiotics for the duration of the trial. The subject must not commence treatment with rhDNase or maintenance antibiotics during the trial; 3. Have a confirmed diagnosis of cystic fibrosis (sweat test result >= 60 mEq/L chloride and/or genotyping showing two identifiable mutations consistent with a diagnosis of cystic fibrosis); 4. Be aged >= 6 years and < 18 years; 5. Have a percentage of predicted FEV1 of >= 30% and < 90% at Screening (Visit 0). Percentage of predicted FEV1 will be calculated using Wang for children aged < 8 years, and using NHanes III for those >= 8 years; and 6. Be able to perform all the techniques necessary to measure lung function.
Are the trial subjects under 18? yes Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range 0 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria: 1. Be using maintenance nebulised hypertonic saline Be considered “terminally ill”; eligible for lung transplantation, or have received a lung transplant previously; 2. Require home oxygen or assisted ventilation; 3. Have had an episode of massive haemoptysis defined as acute bleeding =240 ml in a 24-hour period and/or recurrent bleeding =100 ml/day over several days in the three-months prior to Screening (Visit 0);
4. Have a known intolerance to mannitol; 5. Be taking non-selective beta blockers; 6. In the three months prior to Screening (Visit 0) have had a myocardial infarction; a cerebral vascular accident; major ocular, abdominal, chest or brain surgery; 7. Have a known cerebral, aortic or abdominal aneurysm; 8. Be currently participating in, or have participated in another investigative drug trial within four weeks of Screening (Visit 0); 9. Be pregnant or breastfeeding, or plan to become pregnant whilst in the trial; 10. For females of childbearing potential (at the discretion of the investigator), be using an unreliable form of contraception; 11. Have a “failed” or “incomplete” mannitol tolerance test; or 12. Have any concomitant medical, psychiatric, or social condition that, in the Investigator’s opinion, would put the subject at significant risk, may confound the results or may significantly interfere with the subject’s participation in the trial.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Cystic fibrosis in children aged 6 to 17 years
MedDRA version: 14.1
Level: PT
Classification code 10011762
Term: Cystic fibrosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
|
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
Intervention(s)
|
Trade Name: Bronchitol Product Name: Bronchitol Product Code: N/A Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: mannitol CAS Number: 69-95-8 Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Inhalation powder, hard capsule Route of administration of the placebo: Inhalation use
|
Primary Outcome(s)
|
Primary end point(s): The absolute change from each baseline to week 8 of each treatment period in percentage of predicted FEV1.
|
Secondary Objective: • To determine the effect of inhaled mannitol on FVC; • To determine the effect of inhaled mannitol on FEF25-75 (exploratory objective) and • To assess the safety of inhaled mannitol. • To evaluate the difference in treatment induced sputum weight in patients treated with inhaled mannitol compared to those treated with placebo
|
Main Objective: To determine the effect of eight weeks of twice-daily treatment with inhaled dry powder mannitol on lung function (FEV1) in subjects with CF who are aged six to seventeen years
|
Timepoint(s) of evaluation of this end point: Endpoint will be evaluated at the end of the trial.
|
Secondary Outcome(s)
|
Secondary end point(s): • Change in percentage of predicted FVC between placebo and mannitol treatment • Change in percentage of predicted FEF25-75 between placebo and mannitol treatment (exploratory endpoint) • Adverse events, vital signs and physical examination • Treatment induced sputum weight
|
Timepoint(s) of evaluation of this end point: Endpoints will be evaluated at the end of the trial.
|
Secondary ID(s)
|
DPM-CF-204
|
Source(s) of Monetary Support
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|